{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:00:09Z","timestamp":1789747209520,"version":"4.0.1"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1097\/mpa.0000000000000710","type":"journal-article","created":{"date-parts":[[2016,9,30]],"date-time":"2016-09-30T09:08:42Z","timestamp":1475226522000},"page":"1485-1493","source":"Crossref","is-referenced-by-count":9,"title":["Precision Medicine and Pancreatic Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"James J.","family":"Farrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Moughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan L.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William F.","family":"Regine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Schaefer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al B.","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhong","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerold","family":"Bepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandan","family":"Guha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hany","family":"Elsaleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210212","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N Engl J Med"},{"key":"R2-20-20210212","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R3-20-20210212","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","article-title":"Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group","volume":"25","author":"Moore","year":"2007","journal-title":"J Clin Oncol"},{"key":"R4-20-20210212","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1001\/jama.299.9.1019","article-title":"Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial","volume":"299","author":"Regine","year":"2008","journal-title":"JAMA"},{"key":"R5-20-20210212","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/j.gastro.2008.09.067","article-title":"Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer","volume":"136","author":"Farrell","year":"2009","journal-title":"Gastroenterology"},{"key":"R6-20-20210212","doi-asserted-by":"crossref","first-page":"6956","DOI":"10.1158\/1078-0432.CCR-04-0224","article-title":"The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma","volume":"10","author":"Spratlin","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R7-20-20210212","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1053\/j.gastro.2012.06.006","article-title":"Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma","volume":"143","author":"Marechal","year":"2012","journal-title":"Gastroenterology"},{"key":"R8-20-20210212","doi-asserted-by":"crossref","first-page":"S558","DOI":"10.1245\/s10434-011-2054-z","article-title":"Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy","volume":"19","author":"Morinaga","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R9-20-20210212","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.surg.2012.10.010","article-title":"Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection","volume":"153","author":"Nakagawa","year":"2013","journal-title":"Surgery"},{"key":"R10-20-20210212","doi-asserted-by":"crossref","first-page":"S646","DOI":"10.1245\/s10434-011-2140-2","article-title":"Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection","volume":"19","author":"Kondo","year":"2012","journal-title":"Ann Surg Oncol"},{"key":"R11-20-20210212","doi-asserted-by":"crossref","first-page":"djt347","DOI":"10.1093\/jnci\/djt347","article-title":"Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial","volume":"106","author":"Greenhalf","year":"2014","journal-title":"J Natl Cancer Inst"},{"key":"R12-20-20210212","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.2013.51.0826","article-title":"Randomized, multicenter, phase II study of CO-101 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma: including a prospective evaluation of the role of hENT1 in gemcitabine or CO-101 sensitivity","volume":"31","author":"Poplin","year":"2013","journal-title":"J Clin Oncol"},{"key":"R13-20-20210212","first-page":"258","article-title":"Human equilibrative nucleoside transporter 1 (hENT1) predicts the Asian patient response to gemcitabine-based chemotherapy in pancreatic cancer","volume":"60","author":"Xiao","year":"2013","journal-title":"Hepatogastroenterology"},{"key":"R14-20-20210212","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1158\/1078-0432.CCR-05-2655","article-title":"Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival","volume":"12","author":"Sebastiani","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R15-20-20210212","doi-asserted-by":"crossref","first-page":"5200","DOI":"10.1002\/cncr.25303","article-title":"Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma","volume":"116","author":"Mar\u00e9chal","year":"2010","journal-title":"Cancer"},{"key":"R16-20-20210212","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1038\/onc.2009.158","article-title":"Significance of RRM1 and ERCC1 expression in resectable pancreatic adenocarcinoma","volume":"28","author":"Akita","year":"2009","journal-title":"Oncogene"},{"key":"R17-20-20210212","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/cncr.27619","article-title":"An analysis of human equilibrative nucleoside transporter-1, ribonucleoside reductase subunit M1, ribonucleoside reductase subunit M2, and excision repair cross-complementing gene-1 expression in patients with resected pancreas adenocarcinoma: implications for adjuvant treatment","volume":"119","author":"Fisher","year":"2013","journal-title":"Cancer"},{"key":"R18-20-20210212","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1471-2407-12-104","article-title":"Is there a role for the quantification of RRM1 and ERCC1 expression in pancreatic ductal adenocarcinoma?","volume":"12","author":"Valsecchi","year":"2012","journal-title":"BMC Cancer"},{"key":"R19-20-20210212","first-page":"347","article-title":"Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma","volume":"5","author":"Xie","year":"2012","journal-title":"Int J Clin Exp Pathol"},{"key":"R20-20-20210212","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1053\/j.gastro.2008.11.027","article-title":"Personalized medicine for pancreatic cancer: a step in the right direction","volume":"136","author":"Ko","year":"2009","journal-title":"Gastroenterology"},{"key":"R21-20-20210212","first-page":"3","article-title":"Gemcitabine: preclinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"key":"R22-20-20210212","doi-asserted-by":"crossref","first-page":"27030","DOI":"10.1074\/jbc.M402056200","article-title":"Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(-\/-) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors","volume":"279","author":"Lin","year":"2004","journal-title":"J Biol Chem"},{"key":"R23-20-20210212","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1053\/j.seminoncol.2006.10.005","article-title":"Adjuvant therapy for pancreatic cancer: current status, future directions","volume":"33","author":"Regine","year":"2006","journal-title":"Semin Oncol"},{"key":"R24-20-20210212","doi-asserted-by":"crossref","first-page":"30239","DOI":"10.1074\/jbc.273.46.30239","article-title":"The intracellular localization of deoxycytidine kinase","volume":"273","author":"Hatzis","year":"1998","journal-title":"J Biol Chem"},{"key":"R25-20-20210212","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1056\/NEJMoa065411","article-title":"DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer","volume":"356","author":"Zheng","year":"2007","journal-title":"N Engl J Med"},{"key":"R26-20-20210212","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1042\/CS20120240","article-title":"Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers","volume":"124","author":"Liu","year":"2013","journal-title":"Clin Sci (Lond"},{"key":"R27-20-20210212","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1158\/0008-5472.CAN-11-0054","article-title":"Ribonucleotide reductase small subunit M2B prognoses better survival in colorectal cancer","volume":"71","author":"Liu","year":"2011","journal-title":"Cancer Res"},{"key":"R28-20-20210212","doi-asserted-by":"crossref","first-page":"6337","DOI":"10.1158\/1078-0432.CCR-06-0799","article-title":"Metastasis-suppressing potential of ribonucleotide reductase small subunit p53R2 in human cancer cells","volume":"12","author":"Liu","year":"2006","journal-title":"Clin Cancer Res"},{"key":"R29-20-20210212","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1038\/bjc.2013.108","article-title":"Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer","volume":"108","author":"Eto","year":"2013","journal-title":"Br J Cancer"},{"key":"R30-20-20210212","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/s00534-011-0440-3","article-title":"Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabine-based chemoradiotherapy","volume":"19","author":"Murata","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R31-20-20210212","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00534-012-0514-x","article-title":"Human equilibrative nucleoside transporter 1 level does not predict prognosis in pancreatic cancer patients treated with neoadjuvant chemoradiation including gemcitabine","volume":"19","author":"Kawada","year":"2012","journal-title":"J Hepatobiliary Pancreat Sci"},{"key":"R32-20-20210212","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.1158\/0008-5472.CAN-05-4203","article-title":"Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine","volume":"66","author":"Giovannetti","year":"2006","journal-title":"Cancer Res"},{"key":"R33-20-20210212","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1593\/neo.10458","article-title":"Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy","volume":"12","author":"Fujita","year":"2010","journal-title":"Neoplasia"},{"key":"R34-20-20210212","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bjc.6603559","article-title":"Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells","volume":"96","author":"Nakano","year":"2007","journal-title":"Br J Cancer"},{"key":"R35-20-20210212","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0959-8049(00)00246-X","article-title":"Cross-resistance in the 2',2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000 to standard and investigational drugs","volume":"36","author":"Bergman","year":"2000","journal-title":"Eur J Cancer"},{"key":"R36-20-20210212","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3892\/ijo.2013.1899","article-title":"Involvement of ribonucleotide reductase-M1 in 5-fluorouracil induced DNA damage in esophageal cancer cell lines","volume":"42","author":"Aoki","year":"2013","journal-title":"Int J Oncol"},{"key":"R37-20-20210212","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1002\/ijc.22390","article-title":"Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer","volume":"120","author":"Nakahira","year":"2007","journal-title":"Int J Cancer"},{"key":"R38-20-20210212","first-page":"473","article-title":"Predicting the chemosensitivity of pancreatic cancer cells by quantifying the expression levels of genes associated with the metabolism of gemcitabine and 5-fluorouracil","volume":"39","author":"Kurata","year":"2011","journal-title":"Int J Oncol"},{"key":"R39-20-20210212","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/cncr.27715","article-title":"Predictive and prognostic roles of ribonucleotide reductase M1 in resectable pancreatic adenocarcinoma","volume":"119","author":"Xie","year":"2013","journal-title":"Cancer"},{"key":"R40-20-20210212","doi-asserted-by":"crossref","first-page":"3126","DOI":"10.1002\/cncr.25883","article-title":"Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer","volume":"117","author":"Kim","year":"2011","journal-title":"Cancer"},{"key":"R41-20-20210212","first-page":"3475","article-title":"Expression status of ribonucleotide reductase small subunits hRRM2\/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer","volume":"31","author":"Hsu","year":"2011","journal-title":"Anticancer Res"},{"key":"R42-20-20210212","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1093\/annonc\/mdl300","article-title":"ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine","volume":"17","author":"Ceppi","year":"2006","journal-title":"Ann Oncol"},{"key":"R43-20-20210212","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s00280-006-0297-3","article-title":"A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression","volume":"59","author":"Shibata","year":"2007","journal-title":"Cancer Chemother Pharmacol"},{"key":"R44-20-20210212","doi-asserted-by":"crossref","first-page":"4731","DOI":"10.1200\/JCO.2006.06.1101","article-title":"RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer","volume":"24","author":"Bepler","year":"2006","journal-title":"J Clin Oncol"},{"key":"R45-20-20210212","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s00535-007-2017-0","article-title":"Ribonucleotide reductase subunit M2 mRNA expression in pretreatment biopsies obtained from unresectable pancreatic carcinomas","volume":"42","author":"Itoi","year":"2007","journal-title":"J Gastroenterol"},{"key":"R46-20-20210212","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1158\/1078-0432.CCR-1183-3","article-title":"Inhibition of SRC tyrosine kinase impairs inherent and acquired gemcitabine resistance in human pancreatic adenocarcinoma cells","volume":"10","author":"Duxbury","year":"2004","journal-title":"Clin Cancer Res"},{"key":"R47-20-20210212","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.bbrc.2006.12.177","article-title":"RRM2 induces NF-kappaB-dependent MMP-9 activation and enhances cellular invasiveness","volume":"354","author":"Duxbury","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"R48-20-20210212","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/35003506","article-title":"A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage","volume":"404","author":"Tanaka","year":"2000","journal-title":"Nature"},{"key":"R49-20-20210212","first-page":"980","article-title":"Wild-type p53 regulates human ribonucleotide reductase by protein-protein interaction with p53R2 as well as hRRM2 subunits","volume":"63","author":"Xue","year":"2003","journal-title":"Cancer Res"},{"key":"R50-20-20210212","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1158\/1078-0432.CCR-05-2416","article-title":"Expression of p53R2 is related to prognosis in patients with esophageal squamous cell carcinoma","volume":"12","author":"Okumura","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Pancreas"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPA.0000000000000710","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:42:25Z","timestamp":1620963745000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006676-201611000-00020"}},"subtitle":["A Gemcitabine Pathway Approach"],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1097\/mpa.0000000000000710","relation":{},"ISSN":["0885-3177"],"issn-type":[{"value":"0885-3177","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]}}}